<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04905654</url>
  </required_header>
  <id_info>
    <org_study_id>H-20049785</org_study_id>
    <nct_id>NCT04905654</nct_id>
  </id_info>
  <brief_title>Migraine Inducing Effect of Levcromakalim in Patients With Migraine With Aura</brief_title>
  <official_title>Migraine Inducing Effect of Levcromakalim in Patients With Migraine With Aura</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danish Headache Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Danish Headache Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the migraine inducing effect of levcromakalim in patients with migraine with&#xD;
      aura.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 29, 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Headache incidence</measure>
    <time_frame>10 minutes before until 24 hours after infusion of levcromakalim or placebo</time_frame>
    <description>Difference in incidence of headache following infusion of levcromakalim compared to placebo in patients with migraine with aura.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Migraine incidence</measure>
    <time_frame>10 minutes before until 24 hours after infusion of levcromakalim or placebo</time_frame>
    <description>Difference in incidence of migraine-like headache following infusion of levcromakalim compared to placebo in patients with migraine with aura.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aura incidence</measure>
    <time_frame>10 minutes before until 24 hours after infusion of levcromakalim or placebo</time_frame>
    <description>Difference in incidence of migraine aura following infusion of levcromakalim compared to placebo in patients with migraine with aura.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Headache intensity</measure>
    <time_frame>10 minutes before until 24 hours after infusion of levcromakalim or placebo</time_frame>
    <description>The area under the curve (AUC) for headache following infusion of levcromakalim compared to placebo in patients with migraine with aura</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>10 minutes before until 120 minutes after infusion of levcromakalim or placebo</time_frame>
    <description>Change in heart rate measured in Beats per minute (BPM) following infusion of levcromakalim compared to placebo in patients with migraine with aura</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>10 minutes before until 120 minutes after infusion of levcromakalim or placebo</time_frame>
    <description>Change in blood pressure (systolic and diastolic) measured in mmHg following infusion of levcromakalim compared to placebo in patients with migraine with aura</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Headache, Migraine</condition>
  <condition>Aura</condition>
  <arm_group>
    <arm_group_label>Levcromakalim</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levcromakalim</intervention_name>
    <description>To investigate the role of levcromakalim compared with placebo in migraine with aura patients</description>
    <arm_group_label>Levcromakalim</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>To investigate the role of levcromakalim compared with placebo in migraine with aura patients</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Migraine with aura patients of both sexes.&#xD;
&#xD;
          -  18-60 years.&#xD;
&#xD;
          -  50-100 kg.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Headache less than 48 hours before the tests start&#xD;
&#xD;
          -  Daily consumption of drugs of any kind that investigator deems might affect study&#xD;
             results or safety.&#xD;
&#xD;
          -  Pregnant or nursing women.&#xD;
&#xD;
          -  Cardiovascular disease of any kind, including cerebrovascular diseases.&#xD;
&#xD;
          -  Tension type headache (TTH) according to International Classification of Headache&#xD;
             Disorders version 3 more than 5 times a month on average during the past year&#xD;
&#xD;
          -  Known cluster headache according to International Classification of Headache Disorders&#xD;
             version 3.&#xD;
&#xD;
          -  Psychiatric disorder&#xD;
&#xD;
          -  Smoking or abuse of drugs or alcohol&#xD;
&#xD;
          -  Hypertension (systolic blood pressure &gt;150 mmHg and/or diastolic blood pressure &gt;100&#xD;
             mmHg) on day of inclusion.&#xD;
&#xD;
          -  Hypotension (systolic blood pressure &lt;90 mmHg and/or diastolic blood pressure &lt;50&#xD;
             mmHg) on day of inclusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Messoud Ashina</last_name>
    <role>Study Director</role>
    <affiliation>Danish Headache Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andreas Thomsen, MD</last_name>
    <phone>+4529877971</phone>
    <email>and.v.thomsen@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andreas Thomsen</last_name>
    <phone>+4529877971</phone>
    <email>and.v.thomsen@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Danish Headache Center</name>
      <address>
        <city>Glostrup</city>
        <state>Copenhagen</state>
        <zip>DK-2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Thomsen</last_name>
      <phone>+4529877971</phone>
      <email>and.v.thomsen@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 21, 2021</study_first_submitted>
  <study_first_submitted_qc>May 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2021</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Danish Headache Center</investigator_affiliation>
    <investigator_full_name>Andreas Vinther Thomsen</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Levcromakalim</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Migraine with Aura</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cromakalim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

